James Bilakovics has a vast experience in performing and developing cell-based assays. James has held various positions in different companies such as BPS Bioscience Inc., Takeda San Diego, Inc., Amylin Pharmaceuticals, and Ligand Pharmaceuticals. James's expertise includes evaluating oncology ADC target candidates, developing cardiomyocyte ischemia-reperfusion systems, and discovering target genes for metabolic disease. James has a Bachelor's degree in Biochemistry and Cell Biology from the University of California, San Diego.